- Evolocumab reduced first major cardiovascular events in high-risk patients with diabetes without known atherosclerosis.
- Low-density lipoprotein cholesterol levels were substantially lowered vs placebo.
- Relative risk reduction for major cardiovascular event was about 31%.
- Benefit became more apparent after 1 year.
- Supports earlier use of proprotein convertase subtilisin/kexin type 9 inhibitors in primary prevention.
Source: JAMA
